CN1212841C - 减轻阿扑吗啡的副作用 - Google Patents

减轻阿扑吗啡的副作用 Download PDF

Info

Publication number
CN1212841C
CN1212841C CNB998125210A CN99812521A CN1212841C CN 1212841 C CN1212841 C CN 1212841C CN B998125210 A CNB998125210 A CN B998125210A CN 99812521 A CN99812521 A CN 99812521A CN 1212841 C CN1212841 C CN 1212841C
Authority
CN
China
Prior art keywords
apomorphine
dose
side effects
treatment
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998125210A
Other languages
English (en)
Chinese (zh)
Other versions
CN1324238A (zh
Inventor
R·埃尔－拉施迪
B·隆森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pentech Pharmaceuticals Inc
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of CN1324238A publication Critical patent/CN1324238A/zh
Application granted granted Critical
Publication of CN1212841C publication Critical patent/CN1212841C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNB998125210A 1998-08-24 1999-07-01 减轻阿扑吗啡的副作用 Expired - Fee Related CN1212841C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/138,982 1998-08-24
US09/138,982 US5994363A (en) 1998-08-24 1998-08-24 Amelioration of apomorphine adverse effects
US09/138982 1998-08-24

Publications (2)

Publication Number Publication Date
CN1324238A CN1324238A (zh) 2001-11-28
CN1212841C true CN1212841C (zh) 2005-08-03

Family

ID=22484576

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998125210A Expired - Fee Related CN1212841C (zh) 1998-08-24 1999-07-01 减轻阿扑吗啡的副作用

Country Status (14)

Country Link
US (1) US5994363A (https=)
EP (1) EP1105129A4 (https=)
JP (1) JP2002523370A (https=)
CN (1) CN1212841C (https=)
AU (1) AU764068B2 (https=)
BR (1) BR9913235A (https=)
CA (1) CA2341673A1 (https=)
CZ (1) CZ2001610A3 (https=)
HU (1) HUP0201212A3 (https=)
IL (1) IL141512A0 (https=)
NO (1) NO20010899L (https=)
NZ (1) NZ510359A (https=)
PL (1) PL346273A1 (https=)
WO (1) WO2000010567A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
BR0109515A (pt) 2000-04-07 2004-08-10 Tap Pharmaceutical Prod Inc Derivados da apomorfina e métodos para seu uso
WO2001085013A2 (en) * 2000-05-09 2001-11-15 Nitromed, Inc. Infrared thermography and methods of use
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
JP2004520389A (ja) * 2001-02-08 2004-07-08 ファルマシア・コーポレーション 性的不全の治療のための早期効果発現薬剤
ES2180446B1 (es) * 2001-07-02 2004-01-16 Esteve Labor Dr Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
PL372290A1 (en) * 2002-02-07 2005-07-11 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
KR20050008658A (ko) * 2002-03-19 2005-01-21 마이클 홀릭 아포모르핀의 글리코시드 및 오르토에스테르 글리코시드유도체들, 유사체들 및 그것의 용도
CA2487577C (en) * 2002-05-31 2014-11-18 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
EP1558231A4 (en) * 2002-10-03 2010-09-08 Cypress Bioscience Inc DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
RU2364400C2 (ru) * 2003-04-14 2009-08-20 Вектура Лтд Фармацевтические композиции
AU2005232748A1 (en) * 2004-04-13 2005-10-27 The Mclean Hospital Corporation R(-)-11-hydroxyaporphine derivatives and uses thereof
US20060083724A1 (en) * 2004-10-01 2006-04-20 Hilst Todd W Compositions for the treatment of femal sexual dysfunction
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20110111014A1 (en) * 2007-06-26 2011-05-12 Parkinson's Institute Methods and compositions for treatment of neurological disorders
WO2009009083A1 (en) * 2007-07-12 2009-01-15 The Mclean Hospital Corporation R(-)-2-methoxy-11-hydroxyaporphine and derivatives thereof
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
NZ612686A (en) 2010-12-16 2015-11-27 Cynapsus Therapeutics Inc Sublingual films
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
JP7211706B2 (ja) 2015-04-21 2023-01-24 サノヴィオン ファーマシュティカルズ インコーポレーテッド 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法
IT202100009857A1 (it) 2021-04-19 2022-10-19 Univ Degli Studi Di Torino Formulazione a rilascio controllato e prolungato di apomorfina

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US3976780A (en) * 1968-07-29 1976-08-24 Societe D'etudes Scientifiques Et Industrielles L'ile-De-France Methods of protection against emesis in mammals by administration of a 3-alkoxy-thianaphthene-2-carboxamide
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
AU1508183A (en) * 1982-06-04 1983-12-08 Beecham Group Plc Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane
US4687773A (en) * 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4749700A (en) * 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
US4624965A (en) * 1984-11-15 1986-11-25 Nastech Pharmaceutical Co., Inc. Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same
US4772459A (en) * 1986-09-09 1988-09-20 Erbamont, Inc. Method for controlling emesis caused by chemotherapeutic agents and antiemetic agents useful therein
US4749686A (en) * 1986-12-04 1988-06-07 New York Medical College Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5102887A (en) * 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
JP3310982B2 (ja) * 1994-04-22 2002-08-05 ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド 男性の勃起機能不全を改善するための剤形及び方法
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine

Also Published As

Publication number Publication date
CN1324238A (zh) 2001-11-28
US5994363A (en) 1999-11-30
JP2002523370A (ja) 2002-07-30
HUP0201212A3 (en) 2004-12-28
NO20010899D0 (no) 2001-02-22
NO20010899L (no) 2001-04-24
AU764068B2 (en) 2003-08-07
AU4965199A (en) 2000-03-14
PL346273A1 (en) 2002-01-28
EP1105129A4 (en) 2003-11-12
CA2341673A1 (en) 2000-03-02
HUP0201212A2 (en) 2002-08-28
CZ2001610A3 (cs) 2002-03-13
WO2000010567A1 (en) 2000-03-02
IL141512A0 (en) 2002-03-10
EP1105129A1 (en) 2001-06-13
NZ510359A (en) 2003-06-30
BR9913235A (pt) 2001-12-04

Similar Documents

Publication Publication Date Title
CN1212841C (zh) 减轻阿扑吗啡的副作用
CN1201738C (zh) 用于改善男性勃起机能障碍的含有阿扑吗啡的剂型
CN100346788C (zh) 用于鼻内给药的芬太尼组合物
CN1471393A (zh) 神经性和神经心理性疾病的治疗方法
CN1784221A (zh) 影响体重减轻的组合物
CN1376166A (zh) 降低血液葡萄糖水平的肽
CN1356104A (zh) 全身给药的镇痛方法
CN1805743A (zh) 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
CN1555263A (zh) 治疗普通感冒的组合物
CN1646166A (zh) 用于增强阿片类镇痛剂的方法和组合物
CN101076349A (zh) 使用生长激素促分泌素刺激胃肠系统动力的方法
CN1617715A (zh) 用雄激素受体选择性调节剂治疗肌消耗
CN1849111A (zh) 隐形眼镜用眼科用组合物
CN1334702A (zh) 用每周给药一次或两次的利福拉齐治疗细菌感染的方法
CN1231483C (zh) 8－氮杂二环[3.2.1]辛－2－烯及－辛烷衍生物
CN1750759A (zh) 治疗功能性肠病的方法
CN1117092C (zh) 氮杂双环化合物,其药物组合物及医药用途
CN1076972C (zh) 经皮肤给药的基剂组合物及其药剂组合物
CN1543347A (zh) Bibn4096与其它抗偏头痛药物组合对治疗偏头痛的用途
CN1617723A (zh) 化合物在睡眠障碍等的治疗、在醒时使精力恢复方面的用途以及治疗与之相伴的头晕眼花的方法
CN1066781A (zh) 含有碳酸酐酶抑制剂和β-肾上腺素能拮抗物的眼用组合物
CN1652793A (zh) 雄激素药物组合物和治疗抑郁症的方法
CN101056631A (zh) 治疗阿片类成瘾的芳基（或杂芳基）唑基甲醇衍生物
CN1822836A (zh) 用对苯并二氮杂䓬受体的α3亚基具有选择性的化合物治疗或预防中枢神经系统病症的方法
CN1956710A (zh) 缓解疼痛的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee